A new era of cell therapy has well and truly arrived with the iPSC field setting a trailblazing fire with its potential to develop fully scalable, off-the-shelf cell lines reducing the cost of good
French biopharma company Hybrigenics has made another bid to merge with Belgium's Bone Therapeutics, a specialist in regenerative medicine that is still recovering from a setback in its lea
Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinic
Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells.
Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho